Company: PSTV
Filing Date: 2025-04-30
Form Type: 10-K/A
Source: 0000950170-25-061028
Chunk: 10

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-30
Form: 10-K/A
Chunk 10
---
 known as Rule 10b5-1 plans, by our directors, executive officers and certain other persons. Our policy provides that all Rule 10b5-1 plans must comply with SEC rules applicable to the Rule 10b5-1 safe harbor and imposes additional requirements and limitations.

Director Independence

Our common stock is listed on The Nasdaq Capital Market LLC (“Nasdaq”) and under the listing rules of Nasdaq, subject to specified exceptions, independent directors must comprise a majority of a listed company’s board of directors, and each member of a listed company’s audit, compensation and nominating and corporate governance committees must be independent. Under Nasdaq listing rules, a director will only qualify as an “independent director” if, among other things, the listed company’s board of directors affirmatively determines that the director does not have a relationship which, in the opinion of the listed company’s board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

Our Board reviews the independence of each director. This review is based primarily on responses of the directors to questions in a directors’ and officers’ questionnaire regarding employment, business, familial, compensation and other relationships with Plus and our management. Our Board has determined that no transactions or relationships existed that would disqualify any of our directors under the Nasdaq rules or would require disclosure under SEC rules, with the exception of Marc H. Hedrick, M.D., our President and Chief Executive Officer, because of his current employment relationship with us. In making these determinations, our Board considered the current and prior relationships that each non-employee director has with us and all other facts and circumstances our Board deemed relevant in determining their independence, including the beneficial ownership of our securities by each non-employee director.

Corporate Governance Guidelines

The Board has adopted Corporate Governance Guidelines, which address matters such as the Board’s responsibilities and duties and the Board’s composition and compensation. The Corporate Governance Guidelines are available on our website at https://ir.plustherapeutics.com/governance/corporate-governance-materials.

Board Committees

The Board currently maintains an Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. All members of each of the committees are independent directors under the applicable SEC and Nasdaq rules. Each committee operates under a charter that satisfies the applicable standards of the SEC and Nasdaq. Each committee reviews its respective charter at least annually. The charter for each committee can be found on our website athttps://ir.plusther